Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $128,467.65 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 1,587 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $80.95, for a total value of $128,467.65. Following the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total transaction of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Trading Down 1.5%

Oruka Therapeutics stock opened at $82.16 on Thursday. Oruka Therapeutics, Inc. has a 1-year low of $10.83 and a 1-year high of $91.00. The firm has a market capitalization of $4.96 billion, a PE ratio of -42.35 and a beta of -0.26. The firm’s 50 day simple moving average is $66.06 and its 200 day simple moving average is $46.63.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in ORKA. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the second quarter valued at about $28,000. BNP Paribas Financial Markets boosted its holdings in Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after acquiring an additional 2,306 shares during the period. Royal Bank of Canada grew its position in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on ORKA shares. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the company a “buy” rating in a research note on Monday, April 27th. Barclays lifted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.